

Pfizer temporarily reduces European deliveries of vaccine

January 15 2021, by Jan M. Olsen



A medical worker holding a Pfizer-BioNTech vaccine and a syringe during mass vaccination starts in Vienna, Austria, Friday, Jan. 15, 2021. Authorities started to vaccinate the most vulnerable people in a coordinated effort. (AP Photo/Ronald Zak)

U.S. pharmaceutical company Pfizer confirmed Friday it will temporarily reduce deliveries to Europe of its COVID-19 vaccine while

it upgrades production capacity to 2 billion doses per year.

"This temporary reduction will affect all European countries," a spokeswoman for Pfizer Denmark said in a statement to The Associated Press.

Line Fedders said that to meet the new 2 billion dose target, Pfizer is upscaling production at its plant in Puurs, Belgium, which "presupposes adaptation of facilities and processes at the factory which requires new quality tests and approvals from the authorities."

"As a consequence, fewer doses will be available for European countries at the end of January and the beginning of February," she said.

Germany's Health Ministry said Friday Pfizer had informed the European Commission, which was responsible for ordering vaccines from the company, that it won't be able to fulfill all of the promised deliveries in the coming three to four weeks.

The ministry said German officials took note of the unexpected announcement by the Commission "with regret" because the company had made binding delivery commitments by mid-February.

"The federal and state governments expect the EU Commission to provide clarity and certainty as soon as possible in negotiations with Pfizer about further deliveries and delivery dates," the statement said.

The Commission sealed the vaccine deals on behalf of all 27 member states, but is not responsible for the timetable and deliveries.

Asked Friday whether Brussels has been informed by Pfizer about delays in the EU, Commission health policy spokesman Stefan de Keersmaecker said all questions on production and production capacity

should be directed to the company.



101-year-old Edith Kwoizalla, right, receives her second injection of the Pfizer/BioNTech vaccine against the COVID-19 disease from doctor Bernd Ellendt, center, at a retirement home in Halberstadt, German, Friday, Jan. 15, 2021. (Matthias Bein/dpa via AP)

"The Commission stands ready to support and facilitate contacts between the company and member states whenever needed," he said.

De Keersmaecker said deliveries are made on the basis of purchase orders and specific contracts that are concluded between the member states and the companies.

"The specificities of these arrangements are laid down in these purchase orders or contracts," he said.

The Commission has secured up to 600 million extra doses of the Pfizer vaccine that's produced in partnership with Germany's BioNTech.

Norwegian authorities also said Friday they had been notified by Pfizer about the reduction that will start next week as the company raises its annual dose target from the current 1.3 billion.

"We had predicted 43,875 vaccine doses from Pfizer in week 3. Now it seems that we get 36,075 doses," said Geir Bukholm, director of infection control at the Norwegian Institute of Public Health.

"The stock we now have will be able to compensate for a reduction in the planned deliveries for a few weeks ahead if there is a need for this," he said.

In Finland, broadcaster YLE said the delay would cause domestic delivery problems at the end of January and the beginning of February.

"We expect that this will mean that in the coming time we can vaccinate fewer than first assumed," said Henrik Ullum, head of Statens Serum Institut, a government agency that maps the spread of the coronavirus in Denmark.

© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation: Pfizer temporarily reduces European deliveries of vaccine (2021, January 15) retrieved 26 April 2024 from

<https://medicalxpress.com/news/2021-01-pfizer-covid-vaccine-deliveries-late.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.